Sun Acquires Russian Firm Amid Localization Push
Executive Summary
India's Sun Pharma, the world's fifth largest specialty generic company, has snapped up the Russian firm, JSC Biosintez, raising its stakes in a market that has moved decisively towards import substitution.
You may also be interested in...
Asia Deal Watch: Zogenix Partners Japanese Rights To Pediatric Epilepsy Therapy To Nippon Shinyaku
Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.
Aurobindo Aims For Europe Growth With Apotex Acquisitions
The Indian drug maker is handing over €74m to Canada's Apotex, buying the latter's operations in Poland, the Czech Republic, the Netherlands, Spain and Belgium and adding over 200 generics and more than 80 OTC products to its portfolio.
Aurobindo Aims For Europe Growth With Apotex Acquisitions
The Indian drug maker is handing over €74m to Canada's Apotex, buying the latter's operations in Poland, the Czech Republic, the Netherlands, Spain and Belgium and adding over 200 generics and more than 80 OTC products to its portfolio.